Effects of prazosin treatment on liver enzymes are moderated by alcohol withdrawal symptoms in individuals with alcohol use disorder.
alcohol use disorder
alcohol withdrawal
aspartate transaminase
gamma-glutamyltransferase
prazosin
Journal
Alcohol, clinical & experimental research
ISSN: 2993-7175
Titre abrégé: Alcohol Clin Exp Res (Hoboken)
Pays: United States
ID NLM: 9918609780906676
Informations de publication
Date de publication:
23 Jan 2024
23 Jan 2024
Historique:
revised:
19
12
2023
received:
09
10
2023
accepted:
23
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
aheadofprint
Résumé
Alcohol use disorder (AUD) is associated with significant liver pathology marked by elevated liver enzymes. Prazosin, an alpha1-noradrenergic antagonist significantly improves alcohol drinking outcomes in individuals with alcohol withdrawal symptoms (AW), but effects on liver enzymes are unknown. We assessed the effects of prazosin treatment on the liver enzymes alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase (GGT) in individuals with AUD. Participants (N=100) with AUD were enrolled in a 12-week randomized controlled trial and received either placebo or 16 mg/day of prazosin. Whole blood was drawn from 92 participants to measure liver enzyme levels every 4 weeks, and severity of AW was assessed weekly. Analysis predicting liver function outcomes used linear mixed effects models. Controlling for alcohol consumption, a significant AW × treatment effect was seen for ALT (p < 0.05), AST (p < 0.05) and GGT (p < 0.01). Additionally, AST (b = 0.2, p < 0.01), ALT (b = 0.2, p < 0.05), and GGT (b = 0.3, p < 0.01) were elevated in individuals with higher AW in the placebo but not in the prazosin group (AST: p > 0.66; ALT: p > 0.65). Only in the prazosin group were lower GGT levels associated with higher withdrawal severity (b = -0.16, p < 0.05). We found an interaction of alcohol withdrawal symptoms and prazosin treatment on liver enzyme levels, which were not influenced by week in the trial or the amount of alcohol consumed. Together, these findings suggest that prazosin treatment reduces liver enzymes over the course of AUD treatment among individuals with significant AW, though replication to establish clinical utility is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Alcohol use disorder (AUD) is associated with significant liver pathology marked by elevated liver enzymes. Prazosin, an alpha1-noradrenergic antagonist significantly improves alcohol drinking outcomes in individuals with alcohol withdrawal symptoms (AW), but effects on liver enzymes are unknown. We assessed the effects of prazosin treatment on the liver enzymes alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase (GGT) in individuals with AUD.
METHODS
METHODS
Participants (N=100) with AUD were enrolled in a 12-week randomized controlled trial and received either placebo or 16 mg/day of prazosin. Whole blood was drawn from 92 participants to measure liver enzyme levels every 4 weeks, and severity of AW was assessed weekly. Analysis predicting liver function outcomes used linear mixed effects models.
RESULTS
RESULTS
Controlling for alcohol consumption, a significant AW × treatment effect was seen for ALT (p < 0.05), AST (p < 0.05) and GGT (p < 0.01). Additionally, AST (b = 0.2, p < 0.01), ALT (b = 0.2, p < 0.05), and GGT (b = 0.3, p < 0.01) were elevated in individuals with higher AW in the placebo but not in the prazosin group (AST: p > 0.66; ALT: p > 0.65). Only in the prazosin group were lower GGT levels associated with higher withdrawal severity (b = -0.16, p < 0.05).
CONCLUSIONS
CONCLUSIONS
We found an interaction of alcohol withdrawal symptoms and prazosin treatment on liver enzyme levels, which were not influenced by week in the trial or the amount of alcohol consumed. Together, these findings suggest that prazosin treatment reduces liver enzymes over the course of AUD treatment among individuals with significant AW, though replication to establish clinical utility is needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIMH NIH HHS
ID : R25MH071584-14
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01-AA020504
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01-AA029113
Pays : United States
Informations de copyright
© 2024 Research Society on Alcohol.
Références
Agarwal, S., Fulgoni, V.L. & Lieberman, H.R. (2016) Assessing alcohol intake & its dose-dependent effects on liver enzymes by 24-h recall and questionnaire using NHANES 2001-2010 data. Nutrition Journal, 15, 62.
Albillos, A., Lledó, J.L., Rossi, I., Pérez-Páramo, M., Tabuenca, M.J., Bañares, R. et al. (1995) Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology, 109, 1257-1265.
Barbosa, P.C.R., Tófoli, L.F., Bogenschutz, M.P., Hoy, R., Berro, L.F., Marinho, E.A.V. et al. (2018) Assessment of alcohol and tobacco use disorders among religious users of Ayahuasca. Frontiers in Psychiatry, 9, 136.
Borah, A., Deka, K. & Bhattacharyya, K. (2017) Serum electrolytes and hepatic enzymes level in alcohol withdrawal patients with and without delirium tremens-a comparative study.
CDC. (2022) 2022 Alcohol Related Disease Impact. Available at: https://www.cdc.gov/ARDI [Accessed 9 March 2023]
Conigrave, K.M., Davies, P., Haber, P. & Whitfield, J.B. (2003) Traditional markers of excessive alcohol use. Addiction, 98, 31-43.
Cruise, J., Knechtle, S., Bollinger, R., Kuhn, C. & Michalopoulos, G. (1987) Alpha 1-adrenergic effects and liver regeneration. Hepatology, 7, 1189-1194.
First, M.B., Spitzer, R.L., Gibbon, M. & Williams, J.B.W. (2011) Structured clinical interview for DSM-IV-TR Axis I disorders, research version, non-patient edition. (SCID-I/NP).
Girard, M., Malauzat, D. & Nubukpo, P. (2019) Serum inflammatory molecules and markers of neuronal damage in alcohol-dependent subjects after withdrawal. The World Journal of Biological Psychiatry, 20, 76-90.
Goodson, C.M., Clark, B.J. & Douglas, I.S. (2014) Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcoholism: Clinical and Experimental Research, 38, 2664-2677.
Gough, G., Heathers, L., Puckett, D., Westerhold, C., Ren, X., Yu, Z. et al. (2015) The utility of commonly used laboratory tests to screen for excessive alcohol use in clinical practice. Alcoholism, Clinical and Experimental Research, 39, 1493-1500.
Han, C., Bowen, W.C., Michalopoulos, G.K. & Wu, T. (2008) Alpha-1 adrenergic receptor Transactivates signal transducer and activator of Transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. Journal of Cellular Physiology, 216, 486-497.
Hasin, D.S., Grant, B. & Endicott, J. (1990) The natural history of alcohol abuse: implications for definitions of alcohol use disorders. The American Journal of Psychiatry, 147, 1537-1541.
Iacobucci, D., Schneider, M.J., Popovich, D.L. & Bakamitsos, G.A. (2016) Mean centering helps alleviate “micro” but not “macro” multicollinearity. Behavior Research, 48, 1308-1317.
Kerner, A., Avizohar, O., Sella, R., Bartha, P., Zinder, O., Markiewicz, W. et al. (2005) Association between elevated liver enzymes and C-reactive protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 193-197.
Khajepour, F., Mahmoodpoor, F., Jafari, E., Kakaei, F., Bahraminia, F., Aghajani, S. et al. (2023) Prazosin protects the liver against renal ischemia/reperfusion injury in rats. Drug Research, 73(5), 289-295.
Kuznetsova, A., Brockhoff, P.B. & Christensen, R.H.B. (2017) lmerTest package: tests in linear mixed effects models. Journal of Statistical Software, 82, 1-26.
Litten, R.Z., Ryan, M.L., Falk, D.E., Reilly, M., Fertig, J.B. & Koob, G.F. (2015) Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcoholism, Clinical and Experimental Research, 39, 579-584.
Malcolm, R.J. (2003) GABA systems, benzodiazepines, and substance dependence. The Journal of Clinical Psychiatry, 64(Suppl 3), 36-40.
Michalopoulos, G.K. & DeFrances, M.C. (1997) Liver regeneration. Science, 276, 60-66.
Milivojevic, V. & Sinha, R. (2018) Central and peripheral biomarkers of stress response for addiction risk and relapse vulnerability. Trends in Molecular Medicine, 24, 173-186.
Park, E.Y., Lim, M.K., Oh, J.-K., Cho, H., Bae, M.J., Yun, E.H. et al. (2013) Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. PLoS One, 8, e63439.
Petrakis, I.L., Desai, N., Gueorguieva, R., Arias, A., O'Brien, E., Jane, J.S. et al. (2016) Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. Alcoholism, Clinical and Experimental Research, 40, 178-186.
R Core team. (2023) A language and environment for statsistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/
Randle, L.E., Sathish, J.G., Kitteringham, N.R., Macdonald, I., Williams, D.P. & Park, B.K. (2008) α1-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. British Journal of Pharmacology, 153, 820-830.
Sacks, J.J., Gonzales, K.R., Bouchery, E.E., Tomedi, L.E. & Brewer, R.D. (2015) 2010 National and state costs of excessive alcohol consumption. American Journal of Preventive Medicine, 49, e73-e79.
Schneider, A., Lazo, M., Ndumele, C., Pankow, J.S., Coresh, J., Clark, J. et al. (2013) Liver enzymes, race, gender and diabetes risk: the atherosclerosis risk in communities (ARIC) study. Diabetic Medicine, 30, 926-933.
Simpson, T.L., Saxon, A.J., Meredith, C.W., Malte, C.A., McBride, B., Ferguson, L.C. et al. (2009) A pilot trial of the Alpha-1 adrenergic antagonist, Prazosin, for alcohol dependence. Alcoholism, Clinical and Experimental Research, 33, 255-263.
Simpson, T.L., Saxon, A.J., Stappenbeck, C., Malte, C.A., Lyons, R., Tell, D. et al. (2018) Double-blind randomized clinical trial of Prazosin for alcohol use disorder. American Journal of Psychiatry, 175, 1216-1224.
Sinha, R., Fox, H.C., Hong, K.-I.A., Hansen, J., Tuit, K. & Kreek, M.J. (2011) Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Archives of General Psychiatry, 68, 942-952.
Sinha, R., Wemm, S., Fogelman, N., Milivojevic, V., Morgan, P.M., Angarita, G.A. et al. (2021) Moderation of Prazosin's efficacy by alcohol withdrawal symptoms. American Journal of Psychiatry, 178, 447-458.
Sobell, L.C. & Sobell, M.B. (1992) Timeline follow-back. In: Litten, R.Z. & Allen, J.P. (Eds.) Measuring alcohol consumption: psychosocial and biochemical methods. Totowa, NJ: Humana Press, pp. 41-72.
Sullivan, J.T., Sykora, K., Schneiderman, J., Naranjo, C.A. & Sellers, E.M. (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction, 84, 1353-1357.
Thomes, P.G., Rasineni, K., Saraswathi, V., Kharbanda, K.K., Clemens, D.L., Sweeney, S.A. et al. (2021) Natural recovery by the liver and other organs after chronic alcohol use. Alcohol Research: Current Reviews, 41, 5.
Torkadi, P.P., Apte, I.C. & Bhute, A.K. (2014) Biochemical evaluation of patients of alcoholic liver disease and non-alcoholic liver disease. Indian Journal of Clinical Biochemistry, 29, 79-83.
Turner, R.C., Lichstein, P.R., Peden, J.G., Busher, J.T. & Waivers, L.E. (1989) Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. Journal of General Internal Medicine, 4, 432-444.
van Beek, J.H.D.A., de Moor, M.H.M., Geels, L.M., Sinke, M.R.T., de Geus, E.J.C., Lubke, G.H. et al. (2014) The association of alcohol intake with gamma-glutamyl transferase (GGT) levels: evidence for correlated genetic effects. Drug and Alcohol Dependence, 134, 99-105.
Vatsalya, V., Verster, J.C., Sagaram, M., Royer, A.J., Hu, H., Parthasarathy, R. et al. (2023) Novel paradigms for the gut-brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder. Frontiers in Psychiatry, 14, 1203362.
Weiss, F., Ciccocioppo, R., Parsons, L.H., Katner, S., Liu, X., Zorrilla, E.P. et al. (2001) Compulsive drug-seeking behavior and relapse. Annals of the New York Academy of Sciences, 937, 1-26.
Wetterling, T., Kanitz, R.-D., Veltrup, C. & Driessen, M. (1994) Clinical predictors of alcohol withdrawal delirium. Alcoholism: Clinical and Experimental Research, 18, 1100-1102.
Wilcox, C.E., Tonigan, J.S., Bogenschutz, M.P., Clifford, J., Bigelow, R. & Simpson, T. (2018) A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder. Journal of Addiction Medicine, 12, 339-345.
Xu, J., Murphy, S., Kochanek, K. & Arias, E. (2022) Mortality in the United States, 2021. NCHS Reports.
Yen, C.-H., Ho, P.-S., Yeh, Y.-W., Liang, C.-S., Kuo, S.-C., Huang, C.-C. et al. (2017) Differential cytokine levels between early withdrawal and remission states in patients with alcohol dependence. Psychoneuroendocrinology, 76, 183-191.
Young, G.P., Rores, C., Murphy, C. & Dailey, R.H. (1987) Intravenous phenobarbital for alcohol withdrawal and convulsions. Annals of Emergency Medicine, 16, 847-850.